



Message from CEO, Myron Holubiak on the COVID-19 pandemic

To All of our Employees, Associates, Community, and Stakeholders:

Due to the COVID-19 pandemic, we are implementing several precautionary measures to protect the safety and well-being of all concerned, especially the patients and caregivers involved in our Mino-Lok® Phase 3 Trial. As we confront the challenges posed by this pandemic, we are steadfastly committed to our mission of providing a non-invasive alternative for patients who develop bacteremia due to their central venous lines becoming infected.

Over the last several weeks, we have been closely monitoring the COVID-19 pandemic and have taken significant steps to reduce the risk of exposure to our patients as well as employees, patients, doctors, and health care professionals working on behalf of our Company. We are working with our research sites to provide sufficient supplies of Mino-Lok to assure that any patient meeting the qualifying inclusion criteria in the trial will have uninterrupted access. We have also committed to evaluating an Expanded Access program for those investigators who have requested one. We have reduced all in-person visits and personal contact with our sites until such time as the hospitals allow external visits. During this difficult period, we want to assure everyone that clinical trial coordinators, both from our contract research organization and from our own ranks of clinical professionals, will be available by phone or electronically at all times.

Citius has implemented essential steps to protect the health and welfare of our employees and their families, while at the same time ensuring we continue to serve our patients and clinical trial staff. We have asked all of our employees to work remotely until further notice, restricted all corporate air and train travel, and have instituted an Urgent Issue Team, comprised of our most senior management, which teleconferences daily to address any issues that may arise. We will continue to evaluate our policies as the situation changes.

Let's all Flatten the Curve!

A handwritten signature in blue ink that reads "Myron Z. Holubiak". The signature is fluid and cursive, with the first name being the most prominent.

Myron Z. Holubiak

Chief Executive Officer